CStone Pharmaceuticals (CStone; HKEX: 2616) has received approval to start clinical development of CS1001 in combination with BLU-554 (CS3008) in China in patients with locally advanced or metastatic hepatocellular carcinoma (HCC), it was reported yesterday.
The trial is a multi-centre, open-label, and multi-dose Phase Ib/II study that intends to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumour efficacy of the combination in advanced HCC.
CS1001 is a proprietary anti-PD-L1 monoclonal antibody developed by the company, and one of the company's three backbone immuno-oncology products. Presently, CS1001 is being investigated for the treatment of lung cancer, gastric cancers, and other advanced malignancies. In a Phase Ia study, CS1001 was well-tolerated and showcased anti-tumour activity with partial responses observed in various tumour types.
The US Food and Drug Administration has granted orphan drug designation to BLU-554 for the treatment of HCC.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review